Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Herpes Simplex Clear all
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Results available

EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions

NCT04893577
View directory record Official record
Conditions
Herpes Simplex Oral
Interventions
EDTA, Abreva
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 7, 2026, 6:30 AM EDT
Completed No phase listed Observational

Structure of the Herpes Simplex Virus Receptor

NCT00001648
View directory record Official record
Conditions
Encephalitis, Herpes Simplex, Keratitis, Mouth Disease, Skin Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

NCT03192306
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Merlin, Ethanol
Drug
Lead sponsor
Topical Remedy
Industry
Eligibility
18 Years to 75 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 7, 2026, 6:30 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

NCT00587496
View directory record Official record
Conditions
Herpes Simplex
Interventions
valacyclovir hydrochloride, placebo, valacyclovir plus aspirin
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
20 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth

NCT00006135
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 28 Days
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional

Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT00469300
View directory record Official record
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2008 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072
View directory record Official record
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

NCT05098938
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

NCT01321359
View directory record Official record
Conditions
Recurrent Herpes Simplex Labialis
Interventions
Vehicle versus NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
35
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Netivudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

NCT00448227
View directory record Official record
Conditions
Herpes Simplex
Interventions
famciclovir
Drug
Lead sponsor
Novartis
Industry
Eligibility
1 Month to 1 Year
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

NCT01308424
View directory record Official record
Conditions
Oral Herpes Simplex
Interventions
BTL TML HSV, Matching placebo
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Buffalo, New York • Norwich, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

NCT01324466
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
NB-001, Vehicle
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

NCT05796635
View directory record Official record
Conditions
Cold Sores
Interventions
Herpecin L
Other
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 7, 2026, 6:30 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Hand Sanitizer Use for Herpes Simplex Virus-1

NCT06135844
View directory record Official record
Conditions
Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Interventions
Purell Hand Sanitizer, Medical Grade Mineral Oil
Drug
Lead sponsor
Leciel Bono
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Pocatello, Idaho • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 7, 2026, 6:30 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

NCT00913692
View directory record Official record
Conditions
Herpes Labialis, Herpes Simplex Virus
Interventions
Glutamine, Glycine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

NCT00031460
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 28 Days
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 7, 2026, 6:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 6:30 AM EDT
Not yet recruiting Not applicable Interventional

Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy

NCT06542289
View directory record Official record
Conditions
Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
Interventions
BlinkER device.
Device
Lead sponsor
Neurotrigger Ltd
Industry
Eligibility
22 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 7, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

NCT00297011
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir+clobetasol gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Sep 7, 2026, 6:30 AM EDT